Paracetamol/Codeine Vitabalans

Method of action: Analgesic, Antitussive Opioid, Opioid

Treatment option: Period Pain, Pain, Headache, Toothache, Migraine, Neuralgia

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paracetamol/Codeine Vitabalans

Quick Facts

Property	Description
Active Ingredients	Paracetamol (Acetaminophen), Codeine
Form	Tablet (Oral Dosage Form)
Pharmacological Class	Opioid Analgesic, Combination Analgesic
General Purpose	Relief of moderate to moderately severe pain
Origin/Type	Synthetic/Semi-synthetic derived combination product

What Type of Painkiller is Paracetamol/Codeine Vitabalans?

Paracetamol/Codeine Vitabalans is a specific, prescription-only combination analgesic manufactured by Vitabalans Oy, which firmly belongs to the pharmacological class of opioid analgesics. Its primary purpose, clinically recognized for its efficacy, is to provide robust pain relief for pain considered moderate to moderately severe. This medication is typically prescribed when pain cannot be adequately managed by non-opioid medications alone, such as simple paracetamol. The combination's strength lies in its synergistic effect, a pharmacological property that enhances the total pain-relieving outcome beyond the sum of the individual components.

Composition and Form: Acetaminophen and Codeine

The drug's composition features a fixed-dose combination of two principal chemical substances: paracetamol (acetaminophen) and codeine phosphate. Paracetamol/Codeine Vitabalans is a synthetic/semi-synthetic derived combination product that is manufactured for oral dosage form, specifically presented as a tablet. Paracetamol contributes a non-opiate analgesic and antipyretic activity, while codeine, an opiate derivative, functions as a prodrug that requires enzymatic conversion for its full effect. This conversion mechanism involves codeine's transformation into its active metabolite once absorbed by the body. The defined tablet form ensures precise delivery of both compounds simultaneously.

How Does the Combination Work for Relief?

The therapeutic effect relies on a crucial dual mechanism: central pain signal reduction and opioid-mediated pain blocking. Paracetamol acts centrally to help raise the body's threshold for pain, while the converted morphine (from codeine) binds to mu-opioid receptors to suppress the transmission and modify the patient's perception of pain signals. This comprehensive approach ensures more effective management for pain states that require sustained and multi-faceted analgesic action.

What side effects are possible with Paracetamol/Codeine Vitabalans?

Possible side effects and safety information

The safety profile for this combination medicine, as defined by regulatory authorities, encompasses effects primarily related to the opioid (Codeine) and non-opioid (Paracetamol) components. These effects are classified by frequency and grouped by the body system affected.

Adverse Reaction Frequencies and System Classes

The most frequently documented adverse reactions involve the Gastrointestinal and Nervous Systems. Reactions classified as Very Common in official documentation include constipation, nausea, vomiting, dizziness, and somnolence (sedation). Effects such as headache, pruritus (itching), dry mouth, and increased sweating are typically classified as Common.

Rarely documented reactions involve other system-organ classes, such as severe Blood and Lymphatic System Disorders or serious events affecting the Skin and Subcutaneous Tissue.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights the potential for serious adverse reactions that necessitate strict safety constraints. These include the risk of life-threatening respiratory depression, which is dose-dependent and can be greatest at treatment initiation or dose increase, and the potential for severe hepatotoxicity (liver damage) associated with the Paracetamol component. Prolonged use of the Codeine component is formally associated with the development of drug tolerance and dependence.

Regulatory documentation also defines specific constraints on use. The product is contraindicated in specific populations, including children under 12 years of age, breastfeeding women, and individuals known to be CYP2D6 ultra-rapid metabolizers due to the metabolic risk of increased opioid effect. Caution is also required in patients with severe hepatic or renal impairment.

Overdose and Emergency Response

An overdose of Paracetamol/Codeine presents a critical dual toxicological risk involving both the opioid and acetaminophen components. Overdose manifestations of opioid toxicity may include somnolence, confusion, shallow or slow breathing, pinpoint pupils (miosis), hypotension, and a weak pulse. The most serious acute danger stems from life-threatening respiratory depression.

Paracetamol toxicity may initially present with an absence of symptoms, but it carries the severe risk of progressive, potentially fatal acute liver failure (hepatotoxicity). Other documented manifestations include nausea, vomiting, and abdominal pain. The physiological systems affected are officially documented as the respiratory, central nervous, hepatic, and cardiovascular systems.

Regulatory information requires that immediate medical attention be sought following any suspected overdose, regardless of the patient's current physical state, due to the delayed nature of potential liver damage. Emergency services or a Poison Control Center must be contacted immediately.

The official overdose profile is defined by the necessary rapid intervention with two specific antidotes: Naloxone for the codeine component and N-acetylcysteine (NAC) for the paracetamol component. Supportive management, including activated charcoal and breathing support, is listed as required. Population-specific considerations documented in prescribing information note increased risk in elderly or debilitated patients for respiratory depression, and increased risk for severe hepatotoxicity in those with hepatic insufficiency. Accidental ingestion by children is classified as carrying a risk of fatal overdose.

Therapeutic Uses of Paracetamol/Codeine Vitabalans

This combination analgesic is commonly used to help with symptoms related to moderate to moderately severe physical discomfort, particularly when symptoms create noticeable physiological strain and supportive relief is required. It is applied across domains where additional symptomatic support is needed. It is considered relevant for managing symptoms associated with acute or episodic changes, often used during phases when symptoms become more noticeable.

The medication may be part of symptomatic management for conditions presenting with intense manifestations, such as headache, toothache, post-procedural pain, or musculoskeletal strain. It is also relevant for easing symptom clusters that may become intense or disruptive, including pronounced pain symptoms combined with systemic imbalance like fever.

“This targeted use supports the patient during difficult episodes by easing distress and assists with maintaining comfort and coping during symptomatic periods.”

This approach supports general well-being and contributes to improved day-to-day comfort during symptomatic periods, especially in clinical settings that involve acute symptom patterns.

Quick Fact: Relief for Pain and Fever

Symptom Targeted	Severity	Typical Context
Physical discomfort, Fever	Moderate to Moderately Severe	Acute, Post-procedural, Episodic flares

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use This Medicine

This section outlines the population eligibility and non-eligibility for Paracetamol/Codeine, based strictly on official regulatory documents such as Prescribing Information and Summaries of Product Characteristics (SmPC).

Eligibility Status	Population/Condition
Contraindicated (Must not use)	Children under 12 years of age.
	Individuals known as CYP2D6 Ultra-Rapid Metabolisers.
	Breastfeeding women.
	Adolescents under 18 years post tonsillectomy/adenoidectomy for obstructive sleep apnoea.
	Severe hepatic insufficiency or acute respiratory depression.
Restricted/Conditional Use	Adolescents 12–18 years (use only if other pain relievers fail).
	Patients with impaired renal or hepatic function (mild-to-moderate).
	The elderly or those with decreased respiratory reserve.

The medicine is generally allowed for use in adults who do not possess any of the documented contraindications or high-risk conditions. Regulatory documentation explicitly states that the drug must be avoided in the third trimester of pregnancy due to risks to the neonate. The restrictions are designed to prevent potential harm from codeine's metabolism and paracetamol's effects on the liver, ensuring that high-risk populations are formally excluded from use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several categories of medicines and substances that interact with Paracetamol/Codeine, affecting its safety and efficacy profile. All interaction information is presented at a high, regulatory-aligned descriptive level.

Pharmacodynamic and Metabolic Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated, and a minimum 14-day cessation period is required before starting this medicine. Concomitant use with other Central Nervous System (CNS) Depressants, including alcohol, results in additive CNS depression, raising the risk of profound sedation. Pharmacodynamic conflicts include the potential for Serotonin Syndrome when combined with Serotonergic Drugs (e.g., SSRIs), and the enhancement of the anticoagulant effect when used regularly with agents like Warfarin.

Metabolic interactions center on the CYP enzymes. CYP2D6 Inhibitors (e.g., Fluoxetine) reduce the conversion of codeine to morphine, which may lead to reduced analgesic efficacy. Conversely, certain Hepatic Enzyme Inducers (e.g., Carbamazepine) may increase the risk of Paracetamol hepatotoxicity.

Exposure-Altering Substances

The absorption rate of paracetamol is increased by substances like Metoclopramide or Domperidone and reduced by Cholestyramine. Additionally, co-administration with Flucloxacillin is associated with an increased risk of High Anion Gap Metabolic Acidosis (HAGMA). Other paracetamol or codeine-containing medicines must be avoided to prevent overdose.

Mechanism of Action

The combination of paracetamol and codeine operates through distinct yet converging pathways within the central nervous system (CNS). Paracetamol primarily acts by inhibiting prostaglandin synthesis centrally, likely through activity against an isoform of cyclooxygenase ( COX), which is yet to be fully elucidated. This action results in the modulation of nociceptive signal transmission and the attenuation of afferent central processing of input. Paracetamol also modulates the hypothalamic heat-regulating center, resulting in a reset of core body temperature. Codeine functions as an opioid receptor agonist that mediates cellular signaling by binding to mu-opioid receptors ( MOR) located presynaptically and postsynaptically within the CNS, specifically in regions associated with nociception. Agonism of MOR initiates intracellular consequences, including the inhibition of adenylate cyclase and the hyperpolarization of neurons via enhanced potassium efflux. The synergy of these independent molecular actions leads to combined modulation of central nervous system pathways, influencing pain perception thresholds.

Dosage and Administration Information

Instruction Map: How to use Paracetamol/Codeine Vitabalans

Administration Scope
Route of Administration: Oral administration only.
Dosing Schedule (Adults ≥ 18 years): Standard single dose is one to two tablets (500–1000 mg paracetamol and 30–60 mg codeine). The maximum daily intake must not exceed 8 tablets (4000 mg paracetamol / 240 mg codeine) in 24 hours.
Frequency and Interval: Doses must be separated by a minimum interval of 4–6 hours.
Preparation Requirements: Tablets are to be swallowed whole, typically with water. If a tablet features a score line, this is for ease of swallowing only and not for dividing the tablet into two equal doses.
Course Duration: Treatment is strictly limited to a maximum duration of 3 days.

The official use protocol is structured around a non-negotiable short-term treatment regimen. The medication is intended to be used at the lowest effective dose for the shortest period of time necessary. All patients must ensure the total paracetamol intake from all concurrent products does not exceed the 4000 mg daily limit.

Population-Specific Administration Rules

Age/Condition	Official Procedural Adjustment
Children	The use of codeine is generally not recommended in children under 12 years.
Renal Impairment	The dose interval should be increased to 6 or 8 hours depending on the degree of impairment, to manage the paracetamol component properly.
Hepatic Impairment	A dose reduction or prolonged dosing interval is required, often limiting the total daily paracetamol dose to 2 g or less.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paracetamol/Codeine Vitabalans

The evidence summarized below outlines the types of research that have explored the evaluation of the paracetamol and codeine combination in studies. This information describes what researchers studied and the patterns they reported, without offering any clinical advice, recommendations, or promises about how the medicine may affect an individual.

Evidence for use in Acute Moderate to Severe Pain

Research for this medicine primarily involves short-term Randomized Controlled Trials (RCTs) and comprehensive reviews of these trials, exploring how symptoms change over time in participants experiencing sudden, intense pain, such as that observed after a surgical procedure or acute injury. Studies examine patient-reported outcomes describing perceived discomfort, focusing on the initial hours following administration.

Researchers monitored outcomes related to physical discomfort by tracking changes in pain intensity scores (using scales like the Visual Analogue Scale or NRS) and the proportion of participants who reported achieving a predefined level of pain relief. Findings describe patterns observed in the studies, where the measurements of pain relief thresholds differed between the paracetamol/codeine groups and those receiving an inactive treatment (placebo) over the defined short observation interval. Research so far indicates that these measurements were most commonly studied in adult patients experiencing moderate to severe acute pain.

Long-Term Studies and Follow-Up Data

The body of evidence for the paracetamol/codeine combination is predominantly focused on short-term responses to acute, severe symptoms, with observations rarely extending beyond a single day or, in some cases, a few days. Research examining temporary physiological imbalance and acute pain episodes provides limited data regarding outcomes over longer time intervals.

This means that long-term effects are not fully established or well characterized. There is limited information for long-term outcomes regarding the maintenance of symptom control or the pattern of potential systemic or functional imbalance that may occur with repeated, extended use.

What is Still Uncertain About Paracetamol/Codeine Vitabalans Evidence

The research provides insight into short-term changes, but several aspects remain uncertain or insufficiently studied. The evidence is often derived from trials with sample sizes that were modest, and the follow-up durations were limited, which contributes to uncertainty about outcomes beyond a few hours. Due to known variability, individual response patterns can vary, and findings describe group patterns, not personal outcomes. Researchers continue to identify a need for additional, high-quality studies to fully characterize the range of short-term and intermediate-term responses, especially in groups where current data are insufficient.

Key Studies & References

NICE Guideline NG19: Postoperative pain management (Summary of evidence on short-term efficacy)

Frequently Asked Questions (FAQ)

Common questions about Paracetamol/Codeine Vitabalans (FAQ)

Q: What is Paracetamol/Codeine Vitabalans used for?

A: Paracetamol/Codeine Vitabalans is used to treat moderate pain that is not relieved by other pain relievers like paracetamol or ibuprofen alone. It contains two active ingredients:

Paracetamol (also known as acetaminophen): This helps to relieve pain and reduce fever.
Codeine: This is an opioid analgesic that works in the central nervous system to relieve pain.

Q: How should I take Paracetamol/Codeine Vitabalans?

A: You should always follow your doctor’s or pharmacist’s instructions on how to take this medicine.

Dosage: The dose will depend on the severity of your pain and your individual response. Your doctor will determine the correct dose for you.
Frequency: Doses are usually taken every 4 to 6 hours, as needed for pain relief. You should not exceed the maximum recommended daily dose.
Duration of Use: This medicine should be used for the shortest time possible, and for no more than 3 days for acute pain, unless directed otherwise by a doctor. If pain is not relieved after 3 days, you should consult your doctor.
Administration: The tablets should be swallowed with a sufficient amount of liquid.

Q: What are the common side effects of Paracetamol/Codeine Vitabalans?

A: As with all medicines, this medicine can cause side effects, although not everyone gets them. Common side effects may include:

Drowsiness or dizziness
Constipation
Nausea or vomiting
Headache
Dry mouth
Excessive sweating

If you experience any severe or concerning side effects, you should seek medical advice immediately.

Q: Can I drink alcohol while taking Paracetamol/Codeine Vitabalans?

A: You should not drink alcohol while taking Paracetamol/Codeine Vitabalans. Alcohol can increase the risk of serious side effects, such as drowsiness, dizziness, and respiratory depression (slow or shallow breathing), and can also increase the risk of liver damage from the paracetamol component.

Q: What should I do if I forget a dose?

A: If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten tablet.

Q: Can I take other paracetamol-containing medicines with Paracetamol/Codeine Vitabalans?

A: No, you should not take any other medicines that contain paracetamol (acetaminophen) while you are taking Paracetamol/Codeine Vitabalans. This is because Paracetamol/Codeine Vitabalans already contains a dose of paracetamol. Taking additional paracetamol products can lead to an overdose and cause serious liver damage.

Always check the ingredients of other cold, flu, or pain relief medicines to ensure they do not contain paracetamol.

Q: Is Paracetamol/Codeine Vitabalans addictive?

A: Codeine is an opioid and there is a risk of dependence and addiction with repeated use, which can lead to withdrawal symptoms if you stop taking it suddenly. This risk increases with higher doses and longer duration of use. This is one reason why the medicine is recommended for short-term use only (maximum 3 days) for acute pain.

If you are concerned about dependence, you should discuss this with your doctor or pharmacist.

How should Paracetamol/Codeine Vitabalans be stored and disposed of?

How to Store and Dispose of Paracetamol/Codeine Vitabalans?

Regulatory documentation mandates specific conditions for storing and disposing of this combination analgesic, especially due to its controlled substance component (Codeine).

Storage Requirement	Rule
Temperature and Environment	Store at room temperature (below 25 C) and keep away from excess heat, moisture, and direct light. Do not freeze or store in high-humidity areas like bathrooms.
Security and Access	Keep out of the sight and reach of children. The medication must be secured in a locked cabinet or drawer to prevent accidental ingestion or diversion.
Packaging	Keep the tablets in their original container, tightly closed, until the marked expiration date.
Disposal	Do not flush down the toilet or throw into household trash without preparation. The preferred disposal method is to use a drug take-back program. If unavailable, mix the tablets with an undesirable substance (like dirt or coffee grounds), place in a sealed bag, and discard with household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Estonia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z